alpha-synuclein and coumarin

Pathological protein inclusion formation and propagation are the main causes of neuronal dysfunction in diverse neurodegenerative diseases; therefore, current disease-modifying therapeutic strategies have targeted this disease protein aggregation process. Recently, we reported that peucedanocoumarin III (PCiii) is a promising therapeutic compound with the ability to disaggregate α-synuclein inclusion and protect dopaminergic neurons in Parkinson's disease (PD). Here, we found that

Topics: alpha-Synuclein; Animals; Coumarins; Disease Models, Animal; Dopaminergic Neurons; Mice; Parkinson Disease; Rats; Synucleinopathies